Slide 1: First Quarter 2024 Earnings
First Quarter 2024 Earnings April 29, 2024
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Transformation Performance Recent Life Science leadership change cements Upside driven by Software Launched Signals Clinical integration strategy and Diagnostics offsetting and Signals ChemDraw to challenging Pharma build on existing SaaS Cash flow process environment capabi
Slide 4: 1Q24 Revenue Highlights
1Q24 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING -DD -LSD +LSD $0.7 B -HSD -LSD $0.7 B +LSD $0.7 B -MSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our we
Slide 5: 1Q24 Financial Results
1Q24 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $650M 25.5% $0.98 $132M -4% y/y -250bps y/y -3% y/y +144% y/y Organic: Adj. Gross Margin: Adj. Tax Rate: Includes $22M of net AES -3% | M&A: 0% | FX: 0% 60.8% | -150bps y/y 22.2% related inflows Adj. Net Interest
Slide 6: Life Sciences
Life Sciences Product REVENUE AJUSTED OP MARGINS REAGENTS INSTRUMENTS SOFTWARE -8% Organic Growth 33.6% -DD -580bps y/y Reported: -8% | M&A: 0% | FX: 0% $303 M • -LDD decline from Pharma/Biotech, -LSD decline from Academic/Gov’t 1Q24 revenue -HSD +HSD • -Mid-teens instruments decline, -HSD decline i
Slide 7: Diagnostics
Diagnostics End Market REVENUE AJUSTED OP MARGINS IMMUNODX REPRODUCTIVE APPLIED HEALTH GENOMICS 1% Organic Growth 21.7% Reported: 0% | M&A: 0% | FX: -1% +30 bps y/y +LSD +LDD $347 M • +LDD ImmunoDX globally, China ImmunoDX +high-teens 1Q24 revenue • +LSD Reproductive Health with +MSD newborn (+LDD e
Slide 8: 2024 Financial Guidance
2024 Financial Guidance REVENUE $2.76B - $2.82B 0% to 3% reported Organic: 1% to 3% FX: 0%, M&A: 0% ADJUSTED OP. MARGIN ~28% ADJUSTED EPS $4.55 - $4.75 Adj. Net interest expense, other: ~$60M Adjusted tax rate: ~20% Average diluted share count: 123.5M 8
Slide 9: Revvity.com
Revvity.com